|Articles|April 1, 2000

Asthma Management Alternatives for the New Millennium
Volume 6
Issue 7 Suppl

Pharmacoeconomic Impact of Inhaled Corticosteroids

Author(s)David A. Stempel, MD

Download PDF: Pharmacoeconomic Impact of Inhaled Corticosteroids

Articles in this issue

over 26 years ago

Article

Participating Faculty

over 26 years ago

Article

Introduction

over 26 years ago

Article

The 1997 Asthma Guidelines and an Asthma Clinical Update

over 26 years ago

Article

Discussion: Implementing the 1997 Asthma Guidelines

over 26 years ago

Article

Overview of HEDIS 2000 Asthma Measurement

over 26 years ago

Article

Discussion: Using the HEDIS Asthma Measurement

over 26 years ago

Article

Understanding Asthma: Gaps in Knowledge and Their Therapeutic Implications

over 26 years ago

Article

Discussion: The Impact of Allergens on Asthma Severity and Treatment

over 26 years ago

Article

Adjunctive Therapy: Treatment Options

over 26 years ago

Article

Discussion: Treatment Options for Asthma

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Impact of Automated Insulin Delivery on Type 2 Diabetes Measures

ByThomas W. Martens, MD,Bimal V. Patel, PharmD, MS,Sharon M. Wang, PharmD, MS,Laurel H. Messer, PhD, MPH, RN, CDCES, BC-ADM,Jordan E. Pinsker, MD,Daniel C. Malone, PhD, RPh,Miranda R. Polin, MS, BS,Diana I. Brixner, PhD, RPh,Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES,Osagie Ebekozien, MD, MPH

July 23rd 2026

Geographical Access to Preferred Pharmacies in Medicare Part D

ByPinka Chatterji, PhD,Yiran Han, PhD,Chun-Yu Ho, PhD

July 22nd 2026

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

ByEmily A. Gadbois, PhD,Jennifer Bunker, MPH,Marguerite Daus, PhD, RN,Jamie M. Smith, PhD, RN,Emily Buss, MSN, RN,Christine D. Jones, MD, MS,Kali S. Thomas, PhD, MA

July 16th 2026

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

ByHeather L. Taylor, MPH, LDH,Ann M. Holmes, PhD,Nir Menachemi, PhD, MPH,Justin Blackburn, PhD

July 10th 2026

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

ByChristopher Scannell, MD, PhD,John A. Romley, PhD,Rebecca Myerson, PhD,Dana Goldman, PhD,Dima Mazen Qato, PharmD, PhD, MPH

July 9th 2026

Pharmacoeconomic Impact of Inhaled Corticosteroids

Articles in this issue

Related Content

Impact of Automated Insulin Delivery on Type 2 Diabetes Measures

Geographical Access to Preferred Pharmacies in Medicare Part D

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

Trending on AJMC

Trump Announces Timeline for 100% Generic Drug Tariffs Beginning in 2028, 200% in 2029

Fifth Death Confirmed in NYC Legionnaires' Outbreak

Pirtobrutinib Plus Venetoclax-Rituximab Cuts CLL Progression 45%

Obesity, Insulin Resistance, and the Silent Progression of MASH: A Hepatologist's Perspective

Small Workflow Changes Close Big Gaps in CKM Screening